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Background: Chagas disease is a parasitic disease caused by the protozoan parasite Trypanosoma cruzi. In Mexico,
the burden of the disease is difficult to estimate and improving surveillance for Chagas disease is an important
priority. We aimed here at determining the seroprevalence of T. cruzi infection in humans in a rural community in
Veracruz.
Methods: Serum samples (196) were analyzed for T. cruzi infection using five enzyme-linked immunosorbent assay
(ELISA) tests: two in-house tests based on crude parasite extract and three commercial ELISA kits. Because of highly
discordant results, we further explored the importance of parasite antigens and strains by western-blot analysis.
Results: A total of 74 samples (37.7 %) were reactive with at least one ELISA, but discordance among tests was very
high. The best agreement was between Chagatest recombinant and Chagatek ELISA (Kappa index = 0.798). The
agreement between other combinations of tests ranged from 0.038 to 0.518. Discordant samples were confirmed
by western-blot analysis using up to nine parasite strains, giving a seroprevalence of 33.7 %.
Conclusions: Commercial tests had a very limited ability to detect T. cruzi infection in the study population.
In-house tests based on crude parasite antigens showed a greater sensitivity but were still unable to detect
all cases of T. cruzi infection, even when based on a local parasite strain. The high seroprevalence confirmed
the hyper-endemicity of T. cruzi infection in the region. Reliable epidemiological surveillance of Chagas
disease will require the development of improved diagnostic tests.
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Chagas disease is a parasitic disease caused by the proto-
zoan parasite Trypanosoma cruzi and transmitted pri-
marily by hematophagous triatomine bugs. The disease
is a major public health problem, affecting 8–10 million
persons worldwide for a disease burden of over 29 mil-
lion disability-adjusted life-years (DALYs), and a global
health care cost reaching $627 billion [1, 2]. The disease
in endemic in the Americas, where vector species are
widespread [3], but it is also becoming globalized due to* Correspondence: angramos@uv.mx
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cate that there are at least 1–2 million infected persons,
but possibly up to 6 million, although T. cruzi infection
remains highly underreported [5, 6] and the true burden
of the disease is difficult to estimate. Updating and im-
proving surveillance and data for Chagas disease in
Mexico should thus be an important priority, and help
improve access to treatment for Mexican patients [7].
Serologic diagnostic for T. cruzi infection has under-
gone great progress in recent years, with the develop-
ment and commercialization of many assays based on
different parasite antigens. Indeed, there has been a shift
in recent years from whole parasite extracts to more
defined recombinant antigen mixtures showing better
specificity [8–10]. The reported sensitivity and specificityhis article is distributed under the terms of the Creative Commons Attribution
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for both). Nonetheless, their actual performance has
been found to be somewhat lower [11] and no gold-
standard has been identified for an accurate and reliable
diagnostic of T. cruzi infection. As a consequence, the
World Health Organization and most National guide-
lines in Latin American countries still recommend the
use of two tests based on different principles and anti-
gens, and in case of discordance, a third test can provide
a final diagnostic.
Differences in test performance have often been attrib-
uted to the parasite stage used for antigen preparation,
with amastigotes, epimastigotes and trypomastigotes po-
tentially having a different antigenic profiles [12, 13].
Also, tests based on whole parasite lysate or crude anti-
gens are believed to be much less reproducible and more
difficult to standardize than those based on recombinant
antigens [8–10]. The diversity of parasite strains has also
been incriminated, leading to the recommendation that
antigens from local strains should be favored to ensure
optimum sensitivity and specificity of the tests. Indeed,
T. cruzi has been divided into at least six discrete typing
units (DTUs), referred to as TcI-TcVI, with very distinct
characteristics [14]. Nonetheless, we previously found a
good agreement between commercial tests, including a
rapid test and a recombinant ELISA test, and an in-
house ELISA based on a crude extract from a local para-
site strain from Mexico [15], suggesting that all these
tests may be useful for the serodiagnostic of T. cruzi
infection in Mexico [16]. ELISA tests based on a variety
of TcI strains from Mexico and Guatemala and the CL-
Brener TcVI strain were found to perform similarly,
suggesting that these strains were equally good sources
of antigens for the detection of T. cruzi infection [17].
Indeed, agreement among tests is relatively high in most
studies [18, 19], although the combination of tests im-
plies that a small proportion of the samples will present
discordant results, which are complicated to manage
from a epidemiological and clinical point of view [19,
20]. Also, a low sensitivity of tests currently used can be
a potential cause of underdiagnosis [11].
In this study, we aimed at determining the seropreva-
lence of T. cruzi infection in humans in a rural commu-
nity in central Veracruz, using a combination of five
ELISA tests based on different antigenic preparations.
Due to highly discordant results, we further explored the
possible role of parasite antigens and strains used in the
serologic diagnostic of T. cruzi infection.
Methods
Serum samples
The study was carried out in the rural community of Las
Josefinas, in central Veracruz, Mexico (−96°41′31″ and
18°28′26″). Information on Chagas disease and on theproject was provided to the inhabitants of the commu-
nity during open meetings organized in the rural med-
ical unit of the community. Interested participants were
given an appointment for themselves and their family to
provide blood samples. The day of the appointment,
written informed consent was obtained from each volun-
teer, and blood samples were collected in vacutainer
tubes. Serum was separated by centrifugation at 1,200 × g
for 10 min and samples were stored at −70 °C until used.
A total of 196 serum samples were collected and analyzed
for T. cruzi infection using five different tests: two in-
house enzyme-linked immunosorbent assay (ELISA)
based on crude parasite extract, three commercial
ELISA diagnostic kits, and a western blot analysis.
In-house ELISA
Two in-house ELISA tests were used, based on epimasti-
gote crude extracts of the CL-Brener (belonging to TcVI
DTU) and LJ01 strains (TDIM/MEX/2014/LJ01/T. cruzi,
a mixture of TcI and non-TcI DTUs, isolated from Tria-
toma dimidiata collected in the village of Las Josefinas,
Veracruz, Mexico), respectively. Both strains were cul-
tured in liver infusion tryptose medium supplemented
with 10 % (w/v) fetal calf serum. Briefly, logarithmic
phase parasites were harvested by centrifugation at
1,000 × g for 10 min at 4 °C. The parasite pellet was sus-
pended in 500 μL of phosphate-buffered saline (PBS)
(137 mM NaCl, 2.7 mM KCl, 4.3 mM Na2HPO4, and
1.4 mM KH2PO4, pH 7.4) and lysed by cycles of freezing
(−70 °C) and thawing (25 °C). The suspension was cen-
trifuged at 10,000 × g for 20 min at 4 °C. The resulting
supernatant (extract) was used as crude antigen extract.
Protein concentration was determined by the Bradford
method. In-house ELISA protocol was performed as fol-
lows, polystyrene plates (Costar Corporation, Cam-
bridge, MA) were coated with the T. cruzi crude antigen
extract (10 μg/mL) in carbonate buffer, pH 9.6, and in-
cubated overnight at 4 °C. Unbound antigen was re-
moved and plates were blocked with 200 μL of PBS
containing 5 % weight/volume (w/v) non-fat milk for 2 h
at 37 °C. After washing with buffer (PBS with 0.05 % w/v
Tween 20), the plates were incubated with 50 μL of
serum samples (1:200 dilution with PBS); each sample
was assayed in duplicate, and plates also included posi-
tive and negative control serum samples. Further wash-
ing steps were performed and a peroxidase labeled goat
anti-human IgG antibody (Pierce, Rockford, IL) was
added at a 1:5,000 dilution in PBS with 0.05 % w/v
Tween 20 and incubated for 1 h at room temperature.
After eight washes, 100 μL of 2,2,-azino-bis (3-ethyl-
benzthiazoline)-6-sulphonic acid (Zymed, San Francisco,
CA) was added as substrate and the reaction was
allowed to proceed for 20 min at room temperature. The
reaction was stopped with 2 % w/v sulfuric acid, and
Fig. 1 Reactivity of human sera with different ELISA tests. Five
different ELISAs were used to identify positive samples to T. cruzi,
two in-house ELISAs (JL01 and CL-Brener extracts), and three
commercial kits. The dotted lines indicate the cut-off line for each
ELISA test
Guzmán-Gómez et al. Parasites & Vectors  (2015) 8:466 Page 3 of 8absorbance was read at 450 nm with an ELISA microplate
reader (Multiscan MS; Labsystems, Vantaa, Finland).
Commercial ELISA diagnostic tests
We use three different commercial ELISA diagnostic
kits, Chagatest ELISA recombinant v3.0 from Wiener
lab (Rosario, Argentina) is based on six recombinant
proteins (1, 2, 13, 30, 36 and SAPA antigens), reported
to be conserved among strains. The manufacturer reports
a sensitivity of 99.3-100 % and a specificity of 98.7–100 %,
and an agreement with other reference methods of 99.6 %.
Chagatek ELISA from Lemos/Biomerieux (Santiago del
Estero, Argentina) is based on purified T. cruzi antigens,
and has a reported sensitivity of 100 % and a specifi-
city of >99 %. The NovaLisa® Chagas (Trypanosoma
cruzi) IgG ELISA from NovaTec Inmunodiagnostica
Gmbh (Dietzenbach, Germany) has a reported sensi-
tivity and specificity of >99 %, and is based on T.
cruzi recombinant antigens. Assays were performed
and cut-off determined according to the respective
manufacturer’s instructions.
Western blot analysis
Western blot was carried out as described before [21]
using a panel of nine different T. cruzi strains from three
DTUs. Briefly, 25 μg of crude antigen extract from the
MHOM/BR/1978/Sylvio-X10 (TcI DTU), CIET1, Camp8,
Nayarit and H1 (all Tc I), MHOM/BR/1950/Y (TcII),
TINF/CL/1945/Tulahuen (TcII), and TINF/BR/1963/
CL-Brener (TcVI) strains were separated by electro-
phoresis in a 10 % sodium dodecyl sulfate–polyacrylamide
gel, 4 replicates were performed and electroblotted onto a
nitrocellulose membrane (Bio-Rad, Hercules, CA) at 80
volts at 4 °C for 1 h. The membranes were blocked with
5 % w/v solution of nonfat milk powder and washed with
TBST buffer (50 mM Tris–HCl, pH 7.4, 150 mM NaCl,
0.05 % Tween 20). The nitrocellulose membrane was indi-
vidually incubated (2 h at 37 °C) with 1 ml of different hu-
man sera diluted 1:100 in TBST with 2 % skim milk.
Control membranes were incubated with positive and
negative serum samples. Each membrane was washed
three times with TBST and subsequently incubated
with alkaline phosphatase–labeled goat anti-human
IgG (Pierce). The membranes were then washed as
above and the immune complexes were developed with
nitrotetrazolium blue (NBT) and 5-bromo-4-chloro-3-
indolyl phosphate (BCIP). The reaction was stopped with
water. Positive, negative, and secondary antibody controls
were included in each experiment.
Statistical analysis
Cut-off OD values for commercial ELISA tests were de-
termined as recommended by each manufacturer. For in
house ELISA tests, the cut-off was defined as the meanOD of negative serum samples (n = 20) plus three stand-
ard deviations. Frequencies of reactive samples were cal-
culated for each ELISA tests. The agreement between
different serological tests was assessed using the Kappa
index. Seroprevalence rates were calculated for sub-
groups of the study population according to sex and age,
as well as their 95 % confidence intervals (CI). Differ-
ences among groups were assessed by Χ2 tests.
Results
ELISA assays
A total of 196 blood samples were collected from inhabi-
tants of the village of Las Josefinas, Veracruz, and tested
with five ELISA tests for T. cruzi antibodies (Fig. 1). A
total of 122 (62.2 %) samples were negative with all the
tests, while 74 (37.7 %) were reactive with at least one
test. However, discordance among tests was very high,
with a total of at least 63/196 (32.1 %) samples with dis-
cordant ELISA results. Only one sample (0.5 %) was re-
active with all five tests, and another one (0.5 %) with
four of the five tests, and thus unambiguously consid-
ered as T. cruzi positives (Table 1). There were an add-
itional nine samples (4.5 %) presenting reactivity in three
ELISA tests, although with different combinations of
tests. Eight samples (4 %) were reactive with NovaLisa®
Chagas IgG test, and the two ELISA with total extracts
from the CL-Brener and LJ01 strains (Table 1), and one
sample (0.5 %) was reactive with Chagatek ELISA
(Laboratorio Lemos/Biomerieux), NovaLisa® Chagas IgG
(NovaTec Inmunodiagnostica), and the LJ01 total extract
ELISA. A further 29 samples (14.8 %) were reactive with
different combinations of two ELISA tests. Sixteen sam-
ples (8.1 %) were reactive with both in-house ELISA
based on total T. cruzi extracts, but with none of the
commercial tests, 12 samples (6.1 %) were reactive with
NovaLisa® Chagas IgG test, and the total extract from
Table 1 Reactivity of samples against different test ELISA
Group Tests Number of reactive
samples (%)LJ01 CL-Brener NovaLisa Chagatek Chagatest
1 R R R R R 1 (0.5 %)
2 R N R R R 1 (0.5 %)
3 R R R N N 8 (4.0 %)
4 R N R R N 1 (0.5 %)
5 R R N N N 16 (8.1 %)
6 R N R N N 12 (6.1 %)
7 N R R N N 1 (0.5 %)
8 R N N N N 23 (11.7 %)
9 N N R N N 9 (4.6 %)
10 N R N N N 2 (1.0 %)
11 N N N N N 122 (62.2 %)
Totala 62 (31.6 %) 28 (14.3 %) 33 (16.8 %) 3 (1.5 %) 2 (1.0 %) 196 (100 %)
Note: The sum of the values and percentages (a) of the last row does not reflect the total number of samples, but refers to the samples which were reactive for
each test
Groups 1–4: Samples reactive for more than three tests
Groups 5–7: Samples reactive for two tests
Groups 8–10: Samples reactive for one test
Group 11: Sample negative for all test
R Reactive, N Negative
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IgG test, and the total extract from the CL-Brener strain.
Finally, an additional 34 samples (17.3 %) were reactive
with a single ELISA test, with 23 samples (11.7 %) reactive
with the in-house ELISA with the LJ01 strain, 9 samples
(4.6 %) were reactive with the NovaLisa® Chagas IgG test,
and another 2 samples (1.0 %) with the CL-Brener ELISA
test only (Table 1).
Based on a minimum of two reactive tests, a total of
40 samples (20.4 %) could thus be considered positive.
However, there was a very poor agreement among tests,
as indicated by very low Kappa indexes (Table 2). In-
deed, the best agreement was between Chagatest recom-
binant 3.0 and Chagatek ELISA, with a Kappa index
reaching 0.798. The agreement between other combina-
tions of tests was very low, with Kappa indexes ranging
from 0.038 to 0.518. Also, it remained unclear whetherTable 2 Kappa index among serological tests
A B C D E
A - 0.518 0.339 0.185 0.044
B - 0.205 0.038 0.049
C - 0.143 0.097
D - 0.798
E -
A: Crude extract LJ01 strain ELISA
B: Crude extract CL-Brener ELISA
C: NovaLisa® Chagas IgG (NovaTec Inmunodiagnostica)
D: Chagatek ELISA (Laboratorio Lemos/Biomerieux)
E: Chagatest Recombinant 3.0 (Wiener)samples with a single reactive ELISA should be consid-
ered as false positive or not.
Western blot assays
Because discordant results from T. cruzi serological test
are often attributed to antigenic differences among para-
site strains/DTUs or among recombinant proteins, we
tested several of the serum samples in western blot as-
says using a panel of T. cruzi crude antigens from several
parasite strains and DTUs, including five TcI, two TcII
and one TcVI strains. As expected, the serum from Sub-
ject J004, which was reactive with all five ELISA tests,
showed a strong banding pattern indicating a reactivity
to many T. cruzi proteins for this serum (Fig. 2). Import-
antly, while the banding pattern varied clearly among
the T. cruzi strains, this sample was strongly reactive
with all strains and DTUs tested. In addition, serum
samples which presented reactivity with different combi-
nations of ELISA tests (Subjects J105 and J008, Fig. 2)
also resulted reactive with different band patterns
against all strains tested. A serum sample that was react-
ive with a single ELISA test was similarly reactive against
all T. cruzi strains tested (Subject J054, Fig. 2). In fact,
the serum samples reactive with a single ELISA (9 react-
ive with NovaLisa® Chagas IgG test, 11 with LJ01 in
house ELISA, and two with CL-Brener ELISA, respect-
ively) and that were tested by western blot resulted all
reactive against both LJ01 and Tulahuen parasite ex-
tracts (Additional file 1: Figure S1). This clearly indi-
cated that these samples were not false positives of their
Fig. 2 Western blot analysis of serum samples against different T. cruzi strains and DTUs. Serum samples were tested for their reactivity against a
panel of eight T. cruzi crude antigen from different strains and DTUs. These include, from left to right: Silvio-X10 (TcI), Ciet-1 (TcI), Camp-8 (TcI),
Nayarit (TcI), Y (TcII), H1 (TcI), Tulahuen (TcII), CL-Brener (TcVI), and LJ01 (Mixture of TcI and non-TcI)
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antibodies.
Seroprevalence in the study population
Based on the combination of ELISA tests and western-
blot confirmation, a total of 62/184 samples (33.7 %;
95%CI [27.3; 40.8]) could thus be confirmed as positive
with at least two tests. Men presented a significantly
higher seroprevalence than women (55 vs 32 %, X2 =
5.63, P = 0.017). Although seroprevalence tended to in-
crease with age, this was not statistically significant (36.8
vs 40.8 % for children <12 years old and >12 years old
subjects, X2 = 0.16, P = 0.68), indicating a very active re-
cent transmission of T. cruzi in this population.
Discussion
We evaluated here the seroprevalence of T. cruzi infec-
tion in humans in a rural community in Veracruz, using
a combination of five ELISA tests based on different
antigenic preparations. Unexpectedly, we found a very
high level of discordance among the ELISA tests used,
with very poor agreement among them. The seropreva-
lence varied from 1–1.5 % with two of the commercial
ELISA up to 31.6 % with an in-house ELISA based on a
crude parasite extract from a local T. cruzi strain. Up to
32 % of the samples presented discordant results among
the ELISA tests and could thus be considered as in-
conclusive. This is contrary to most studies, which
show a relatively good concordance among tests, and
only a 1–2 % of inconclusive results [18, 19]. How-
ever, a study in Brazil also reported a high discord-
ance among hemaglutination, immunofluorescence
and ELISA tests [22].
The reactivity of samples by western blot confirmed
that commercial ELISAs used in our study were very
poorly sensitive for the detection of antibodies against T.
cruzi in the study population. This is contrary to previ-
ous studies in Brazil, which showed that Chagatek
ELISA had a good sensitivity and specificity [19, 23–25].
Similarly, Recombinant Chagastest ELISA also performedwell in Argentina [18], Colombia [26], Brazil [19, 24, 25],
and southern Mexico [15, 16]. We found here that the
most sensitive commercial test was NovaLisa® Chagas IgG
test, detecting a seroprevalence of up to 16.3 %, but this
still represented only half of the total seropositive cases
confirmed by western blot. This test has not been used ex-
tensively so far, but seemed to perform very well in
Colombia [27]. In particular, it presented very limited
cross-reaction (1/7 serum samples) using sera from Leish-
maniasis patients [27].
The differences in performance among commercial
tests may be due to the number and nature of the anti-
gen used, and a larger mixture of antigens may be more
reliable than a few recombinant antigens [18, 28]. This
may also explain why crude parasite lysates, presenting a
very large number of parasite antigens, can be more
sensitive than recombinant antigens [29]. Indeed, the
in-house ELISA tests based on the CL Brener and a
local T. cruzi strain were able to detect the largest
number of reactive serum samples, which were confirmed
by western blot. However, an important drawback of such
crude antigens is their insufficient specificity due to poten-
tial cross-reactivity of sera from leishmaniasis patients
[29], which has motivated the development of test based
on recombinant antigens. In our case, serum samples that
were reactive with in house ELISAS are very unlikely to be
from leishmaniasis patients. Indeed, although leishmania-
sis is known to occur in the state of Veracruz [30], very
few cases have been reported in the region where this
study was performed. In addition, the Chagatek ELISA
test was previously found to effectively react with serum
from leishmaniasis patients (17/21 serum samples)
[24], but gave very few reactive samples in our study
population.
The low sensitivity of the commercial ELISA tests may
also be due to a loss or masking of epitopes in the cor-
responding antigens due to glycosylation and other
post-translational modifications. Indeed, carbohydrates
epitopes have been found to be the target of a substan-
tial part of host immune responses to other parasites
Guzmán-Gómez et al. Parasites & Vectors  (2015) 8:466 Page 6 of 8[31, 32]. In the case of T. cruzi, a recombinant trypo-
mastigote surface protein presented a low sensitivity
for the serologic diagnostic of infection when com-
pared to an indirect immunofluorescence assay [33],
which may indeed be due to a lack of post-translational
modifications of the protein produced in Escherichia
coli. Glycosylation and hydroxylation have also been
found to modulate the reactivity of T. cruzi glycosphin-
golipids fractions with human sera from Chagasic
patients [34].
As previously, western blot was found to be a very
good method for the confirmation of the reactivity of
serum samples against T. cruzi antigens [35]. Import-
antly, it confirmed the reactivity of the serum samples
against a wide variety of parasite strains, covering a large
diversity of local DTUs, as well as strains from other
geographic regions. Although the recognition pattern
somewhat varied according to the strain used, all para-
site extracts were clearly recognized by all serum sam-
ples tested. Nonetheless, western blot remains a test
difficult to perform on large numbers of samples and for
routine diagnostic/confirmation. In addition, only con-
tinuous epitopes are detected in western blots since pro-
teins are denatured, while ELISAs rely on native proteins,
which may result in a higher non-specific background.
Tests based on T. cruzi excreted-secreted antigens (TESA)
have also showed to be good for confirmation of inconclu-
sive serologies [20, 24, 36], but also share the limitation of
been difficult to apply to large number of samples.
Improvement in current commercial ELISA tests is
thus strongly needed. However, even the in-house
ELISA test based on a local strain was unable to de-
tect 11 T. cruzi positive serum samples (5.6 %), which
were detected with the CL-Brener crude antigen or
the NovaLisa® Chagas IgG tests. This suggested that
the LJ01 parasite extract still did not include a reper-
toire of antigenic proteins that covered the entire T.
cruzi diversity in the region. While the genetic diver-
sity of T. cruzi was thought to be limited in Mexico,
with TcI as the predominant DTU [37], several recent
studies have found that other DTUs are also present
and with high frequencies in both Mexico (TcII, TcIII,
TcIV and TcV) and the United States (TcII) [38–40].
Thus, the identification and characterization of new
parasite-specific antigens and epitopes [41–44] cover-
ing a wider range of the parasite antigenic profile
may lead to the development of more specific and
sensitive ELISA tests. Indeed, greater attention to
parasite diversity should be considered for diagnostic
development, similarly to what has been suggested for
drug development [45]. Multiplex serology based on
panels of novel recombinant proteins may provide an
optimum diagnostic tool [46, 47], but need to be
adapted to a test format that is easy to perform forthe processing of large number of samples. In addition,
the use of recombinant proteins expressed in eukaryotic
systems, and thus with post-translational modifications,
may improve their diagnostic accuracy.
Finally, the seroprevalence of T. cruzi infection we de-
tected in the study population is very high, reaching
33.7 %. This confirmed our previous observations in this
area, obtained with different ELISA tests [48]. Also, the
continued presence of active transmission is evidenced
by a high seroprevalence in children < 12 years of age
(36.8 %), also in agreement with a significant house in-
festation by Triatoma dimidiata and its frequent human
feeding [49]. Thus, improved epidemiological surveil-
lance and vector control interventions are urgently
needed in the region.Conclusion
In conclusion, we observed in this study a very high level
of discordance among the ELISA tests used, with very
poor agreement among them. Particularly, the commer-
cial tests had a very limited ability to detect T. cruzi in-
fection in the study population. In-house tests based on
crude parasite antigens showed a greater sensitivity but
were still unable to detect all cases of T. cruzi infection,
even when based on a local parasite strain. Western-blot
allowed the confirmation of an overall seroprevalence of
33.7 %, confirming the hyper-endemicity of T. cruzi in-
fection in this region and the need for extensive epi-
demiological surveillance for a better prevention and
control of Chagas disease. Nonetheless, this will require
the development of improved diagnostic tests for an
accurate detection of cases.Additional file
Additional file 1: Figure S1. Western blot of serum samples against
different T. cruzi strains. Serum samples reactive with a single ELISA test
were confirmed by western blot using crude extract of the T. cruzi LJ01
(A) and Tulahuen (B) strains. These serum samples were reactive with the
LJ01 ELISA (lanes 1–11), CL-Brener ELISA (lanes 12–13), and the NovaLisa®
ELISA (lanes 14–22). C+: positive control serum, C-: negative control
serum. (JPEG 70 kb)
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